The DLL3 expression profile—high, homogeneous cell surface expression in tumors, versus low, cytoplasmic expression in a subset of normal tissues—has enabled the development of therapeutics that use DLL3 to specifically target SCLC cells [20, 35]. Here, DLL3 is linked to small cell lung carcinoma.